专项点评前后硫酸依替米星注射液使用情况分析

Analysis on Clinical Medication of Etimicin Sulfate Injection before and after Special Evaluation

目的:分析某院硫酸依替米星注射液的用药情况,为促进临床合理用药提供参考。方法:抽取医院2017年1月-6月(专项点评前为点评前组)和2018年1月-6月(专项点评后为点评后组)门急诊及住院患者医嘱中使用硫酸依替米星注射液治疗的处方及医嘱,比较专项点评前后硫酸依替米星注射液DDDs值、不合理使用情况和药品不良反应(ADR)发生率差异。结果:通过开展硫酸依替米星注射液专项点评并实施干预后,点评后组药物的DDDs值、不合理用药比例及ADR发生率均低于点评前组(P<0.05);其中点评后组硫酸依替米星注射液门急诊处方、住院医嘱DDDs值分别下降23.02%和13.09%,不合理用药比例分别下降28.30%和40.20%,ADR发生率分别下降80.00%和70.83%。结论:通过临床药师对硫酸依替米星注射液专项点评并实施干预,规范医院硫酸依替米星注射液的临床使用,确保了患者的用药安全性。

Objective:To analyze the clinical medication of etimicin sulfate injection in our hospital,and to provide reference for promoting clinical rational drug use.Methods:Data of doctor’s orders including etimicin sulfate from January to June 2017(the group before special comment)and from January to June 2018(the group after special comment)in the out-patient and emergency department were extracted,comparing DDDs values of etimicin sulfate before and after special comment,unreasonable medication and difference of ADR incidence rates.Results:After the special review and intervention of etimicin sulfate injection,the DDDs value,the proportion of unreasonable use of drugs and the incidence of ADRs in the post-review group were all lower than those in the pre-review group(P<0.05).The DDDsvalues of out-patient and emergency prescriptions and resident orders of etimicin in the review group decreased by 23.02%and 13.09%,the proportion of unreasonable medication decreased by 28.30%and 40.20%,and the incidence of ADRs decreased by 80.00%and 70.83%,respectively.Conclusion:Through the special comment and intervention of clinical pharmacists on etimicin sulfate injection,the clinical medication of etimicin sulfate injection in hospitals was standardized,and the medication safety of patients was ensured.